PROC
protein-codingprotein C, inactivator of coagulation factors Va and VIIIa, the group of Gla domain containing|Receptor ligands
Gene summary
This gene encodes a vitamin K-dependent plasma glycoprotein. The encoded protein is cleaved to its activated form by the thrombin-thrombomodulin complex. This activated form contains a serine protease domain and functions in degradation of the activated forms of coagulation factors V and VIII. Mutations in this gene have been associated with thrombophilia due to protein C deficiency, neonatal purpura fulminans, and recurrent venous thrombosis.[provided by RefSeq, Dec 2009]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~10.8 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0012860
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0008316
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0012860
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0008316
Submitter: PanelApp Australia
Inheritance Pattern: SD
Disease ID:MONDO:0019145
Submitter: ClinGen
PROC was first reported in relation to semidominant hereditary thrombophilia due to congenital protein C deficiency in 1987 (Romeo G, et al., 1987, PMID: 2437584). Over 400 unique variants (primarily missense, but also nonsense, splicing, frameshifts, etc.) have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Variants in this gene have been reported in at least 20 probands in 5 publications (PMIDs: 2437584, 25393254, 11380450, 25618265, and 21621249). Variants in this gene segregated with disease in 14 additional family members. More evidence is available in the literature, but the maximum score for genetic and experimental evidence has been reached. This gene-disease relationship is supported by its biochemical function in factor V and VIII inactivation (PMID: 6791548), its interaction with protein S (PMID: 28514442) and both deficient and null mouse models which recapitulate phenotypes observed in humans (PMID: 15902301, PMID: 9788960). In summary, PROC is definitively associated with semidominant hereditary thrombophilia due to congenital protein C deficiency. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time.
Inheritance Pattern: AD
Disease ID:MONDO:0008316
Submitter: Genomics England PanelApp
Inheritance Pattern: AD
Disease ID:MONDO:0019145
Submitter: Orphanet
Inheritance Pattern: AD
Disease ID:MONDO:0008316
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0012860
Submitter: Labcorp Genetics (formerly Invitae)
Clinical Genomic Database (CGD)
Manifestation: Hematologic
Intervention: Hematologic
Rationale: Individuals can demonstrate manifestations such as severe thrombophilia and high risk for a variety of cardiovascular complications, and prophylactic measures and rapid treatment of sequelae may reduce morbidity and mortality; Liver and renal transplantation have been described
Comments: The risks of hematologic complications may be affected by variants in other genes (eg, FVL)
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to PROC variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_000312.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 5 | 87 | 92 | |||
| missense | 12 | 79 | 160 | 5 | 256 | |
| nonsense | 11 | 8 | 2 | 21 | ||
| start loss | 0 | |||||
| frameshift | 7 | 7 | 1 | 15 | ||
| splice donor/acceptor (+/-2bp) | 3 | 6 | 9 | |||
| Total | 33 | 100 | 168 | 92 | 0 | 393 |
Highest pathogenic variant AF is 0.00023172186
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_000303.1 | 8 | MANE Select | |
| Ensembl | ENSP00000234071.4 | 8 | MANE Select | |
| RefSeq | NP_001362531.1 | 9 | Standard | |
| RefSeq | NP_001362532.1 | 8 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Complement and coagulation cascades - Homo sapiens (human)
- Warfarin Pathway, Pharmacodynamics
- Dengue-2 Interactions with Complement and Coagulation Cascades
- Complement and Coagulation Cascades
- wnt signaling pathway
Biological Process
- proteolysis
- endoplasmic reticulum to Golgi vesicle-mediated transport
- blood coagulation
- negative regulation of blood coagulation
- negative regulation of apoptotic process
Molecular Function
- serine-type endopeptidase activity
- calcium ion binding
- protein binding
Cellular Component
- extracellular region
- extracellular space
- endoplasmic reticulum
- endoplasmic reticulum lumen
- Golgi apparatus
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000234071
- Coding exons
- 8
- Length
- 10820
- Individuals with no LoFs
- 125728
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 18
- Defined
- 125746
- p
- 0.0000716
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 0.883 | 235 | 276 | 0.850 | 0.0000183 | 3044 |
| Missense (PolyPhen) | 73 | 102.86 | 0.70967 | 1133 | ||
| Synonymous | 0.722 | 102 | 112 | 0.913 | 0.00000756 | 863 |
| Loss of Function | 2.03 | 11 | 21.1 | 0.522 | 0.00000110 | 220 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00012 | 0.00012 | rare |
| Latino/Admixed American | 0.00012 | 0.00012 | rare |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0.00027 | 0.00027 | rare |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0.000027 | 0.000026 | rare |
| South Asian | 0.00013 | 0.00013 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Protein C is a vitamin K-dependent serine protease that regulates blood coagulation by inactivating factors Va and VIIIa in the presence of calcium ions and phospholipids (PubMed:25618265). Exerts a protective effect on the endothelial cell barrier function (PubMed:25651845). {ECO:0000269|PubMed:25618265, ECO:0000269|PubMed:25651845}.;
- Disease
- DISEASE: Thrombophilia due to protein C deficiency, autosomal dominant (THPH3) [MIM:176860]: A hemostatic disorder characterized by impaired regulation of blood coagulation and a tendency to recurrent venous thrombosis. Individuals with decreased amounts of protein C are classically referred to as having type I protein C deficiency and those with normal amounts of a functionally defective protein as having type II deficiency. {ECO:0000269|PubMed:1301959, ECO:0000269|PubMed:1347706, ECO:0000269|PubMed:1511989, ECO:0000269|PubMed:1868249, ECO:0000269|PubMed:2437584, ECO:0000269|PubMed:25618265, ECO:0000269|PubMed:25748729, ECO:0000269|PubMed:2602169, ECO:0000269|PubMed:7792728, ECO:0000269|PubMed:7865674, ECO:0000269|PubMed:8292730, ECO:0000269|PubMed:8398832, ECO:0000269|PubMed:8499568, ECO:0000269|PubMed:8560401, ECO:0000269|PubMed:8829639, ECO:0000269|PubMed:9798967}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Thrombophilia due to protein C deficiency, autosomal recessive (THPH4) [MIM:612304]: A hemostatic disorder characterized by impaired regulation of blood coagulation and a tendency to recurrent venous thrombosis. It results in a thrombotic condition that can manifest as a severe neonatal disorder or as a milder disorder with late-onset thrombophilia. The severe form leads to neonatal death through massive neonatal venous thrombosis. Often associated with ecchymotic skin lesions which can turn necrotic called purpura fulminans, this disorder is very rare. {ECO:0000269|PubMed:1511988, ECO:0000269|PubMed:1593215, ECO:0000269|PubMed:1611081, ECO:0000269|PubMed:25618265, ECO:0000269|PubMed:7841323, ECO:0000269|PubMed:7841324, ECO:0000269|PubMed:7878626}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.657
Intolerance Scores
- LoFtool
- 0.0970
- RVIS EVS
- -0.6
- RVIS percentile EVS
- 17.91
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.707
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |